Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$29.04M |
$1.11
+2.78%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$28.60M |
$3.52
-2.35%
|
|
KTCC
Key Tronic Corporation
Vietnam medical device manufacturing capability highlighted, aligning with Medical Devices & Biometrics.
|
$28.55M |
$2.66
-1.48%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$28.22M |
$1.51
+1.34%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$28.19M |
$0.67
+0.26%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$28.17M |
$4.35
+0.23%
|
|
HBIO
Harvard Bioscience, Inc.
HBIO generates recurring revenue from consumables used with its medical devices and bioproduction platforms (biochips, reagents, etc.).
|
$28.07M |
$0.65
+0.12%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$27.91M |
$6.94
|
|
DRIO
DarioHealth Corp.
Integrated Medical Devices & Biometrics (smart glucose meters and biofeedback sensors) are part of the offering.
|
$27.66M |
$12.30
+1.15%
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$27.60M |
$0.61
-3.20%
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$27.27M |
$0.30
-0.59%
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$27.27M |
$1.17
-4.10%
|
|
MODD
Modular Medical, Inc.
MODD directly manufactures insulin pumps (MODD1 and Pivot), a core medical device product category categorized under Medical Devices & Biometrics.
|
$26.99M |
$0.50
+3.12%
|
|
YI
111, Inc.
Private label medical devices and biometrics offerings under the healthcare product lineup.
|
$26.73M |
$2.99
+4.91%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$26.69M |
$2.04
-1.45%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$26.62M |
$6.87
-4.45%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$26.21M |
$0.60
+2.54%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$26.17M |
$2.65
-0.38%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$26.04M |
$2.48
-5.53%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$25.97M |
$1.42
-1.74%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$25.93M |
$0.33
+9.43%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$25.88M |
$2.02
-2.66%
|
|
PLUR
Pluri Inc.
PluriCDMO provides cell-therapy manufacturing services, generating revenue and serving as a core business line.
|
$24.88M |
$3.04
+1.00%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$24.54M |
$1.55
-6.33%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$24.24M |
$22.26
-1.15%
|
|
PIII
P3 Health Partners Inc.
Healthcare Services & Facilities
|
$23.36M |
$3.65
+7.82%
|
|
RVP
Retractable Technologies, Inc.
Core product category directly manufactured and sold: passive-safety syringes designed to prevent needlestick injuries.
|
$23.09M |
$0.77
-1.59%
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$22.67M |
$1.89
+10.88%
|
|
MLSS
Milestone Scientific Inc.
Direct dental equipment manufacturing (DPS-based systems and related dental devices) as the dental segment is a core business.
|
$22.55M |
$0.29
-0.66%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$21.75M |
$1.07
-1.38%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$21.51M |
$0.91
+8.02%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$21.15M |
$0.37
-8.39%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$20.88M |
$1.75
+6.71%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$20.87M |
$0.61
-3.52%
|
|
EKSO
Ekso Bionics Holdings, Inc.
Product portfolio includes Ekso Indego Personal and EksoNR, both medical devices used for rehabilitation and mobility assistance.
|
$20.71M |
$8.00
-2.32%
|
|
NSYS
Nortech Systems Incorporated
Medical Device Components manufacturing and assembly for regulated markets.
|
$20.48M |
N/A
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
VTGN
VistaGen Therapeutics, Inc.
Pherine platform represents a non-systemic intranasal drug-delivery approach developed by the company.
|
$20.25M |
$0.67
-4.63%
|
Showing page 31 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
